Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$12 Mln
P/E Ratio
--
P/B Ratio
0.25
Industry P/E
--
Debt to Equity
0.03
ROE
-1.11 %
ROCE
-109.02 %
Div. Yield
0 %
Book Value
1.18
EPS
-2.55
CFO
$-248.63 Mln
EBITDA
$-288.67 Mln
Net Profit
$-287.74 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Athira Pharma Inc (ATHA)
| -50.55 | -4.89 | -44.11 | -84.89 | -69.70 | -- | -- |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
|
|---|---|---|---|---|
|
Athira Pharma Inc (ATHA)
| -75.57 | -23.34 | -75.67 | -61.96 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.58 | 10,315.11 | 21.27 | 23.13 | |
| 304.46 | 8,705.27 | 22.77 | 66.44 | |
| 27.63 | 10,589.59 | -- | -28.77 | |
| 108.19 | 10,559.67 | 32.44 | 14.16 |
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis,... which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington. Address: 18706 North Creek Parkway, Bothell, WA, United States, 98011 Read more
President, CEO & Director
Dr. Mark J. Litton M.B.A., Ph.D.
President, CEO & Director
Dr. Mark J. Litton M.B.A., Ph.D.
Headquarters
Bothell, WA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Athira Pharma Inc (ATHA) stood at $ 59 Mln as on 31-Dec-24
The share price of Athira Pharma Inc (ATHA) is $0.29 (NASDAQ) as of 29-Apr-2025 13:16 EDT. Athira Pharma Inc (ATHA) has given a return of -69.7% in the last 3 years.
Athira Pharma Inc (ATHA) has a market capitalisation of $ 12 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Athira Pharma Inc (ATHA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Athira Pharma Inc (ATHA) and enter the required number of quantities and click on buy to purchase the shares of Athira Pharma Inc (ATHA).
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington. Address: 18706 North Creek Parkway, Bothell, WA, United States, 98011
The CEO & director of Dr. Mark J. Litton M.B.A., Ph.D.. is Athira Pharma Inc (ATHA), and CFO & Sr. VP is Dr. Mark J. Litton M.B.A., Ph.D..
There is no promoter pledging in Athira Pharma Inc (ATHA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Athira Pharma Inc (ATHA) | Ratios |
|---|---|
|
Return on equity(%)
|
-110.77
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Athira Pharma Inc (ATHA) was $0 Mln.
$0.00
(
